Genomma Lab Delivers Outstanding Top Line Growth of 57.9% and EBITDA[1] Growth of 43.6% in 3Q 2009

GENOMMA LAB INTERNACIONAL ANNOUNCES THIRD QUARTER 2009 RESULTS

Mexico City, Mexico – October 26, 2009

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), announced today its results for the quarter ended September 30, 2009. All figures included herein were prepared in accordance with Mexican GAAP; figures are stated in nominal Mexican pesos. Also, the following consolidated figures show the Company's Spanish operations reclassified as discontinued operations according to Mexican GAAP.

3Q09 Highlights (vs. 3Q08)

- During the third quarter of 2009, the Company launched *Primer Nivel Por Tu Salud* generic pharmaceuticals brand; the launch included 167 medical prescription ("RX") and over the counter pharmaceuticals ("OTC") products.
- Also, during the third quarter, Genomma Lab signed a strategic alliance agreement with Grupo Televisa S.A.B. de C.V. [NYSE: TV] to market and distribute OTC and personal care products in the U.S. and Puerto Rico.
- Net Sales for the quarter reached Ps. 1,123.7 million, an increase of 57.9%
- EBITDA[1] increased 43.6%, to Ps. 296.8 million. This represents a 26.4% margin during the period.
- Earnings per Share[2] increased 37.5%, to Ps. 1.09.
- International Net Sales rose 295.9%, to Ps. 187.8 million.
- During the third quarter, Genomma Lab successfully launched four products under three existing brands (Base Brands[3] and Prior Year Launches[4]) as part of our line extension strategy.
- The Company also launched six products under four New Brands[5], as part of its new product launch plan during the third quarter.

[1] EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income.
[2] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period.
[3] As defined below.
[4] As defined below.
[5] As defined below.

Investor Relations Contact: Oscar Villalobos
Tel: +52 (55) 5081 0000 Ext. 4250
E-mail: inversion@genommalab.com

In New York: i-advize Corporate Communications, Inc.
Tel: (212) 406-3692
E-mail: genomma@i-advize.com

Comments from the Chairman and CEO

Mr. Rodrigo Herrera, Chairman and Chief Executive Officer, stated: "We are pleased to report Genomma Lab's third quarter 2009 results, which demonstrate outstanding growth and profitability. We are delighted to see that consumer demand for our products remained strong during the third quarter. We will remain cautious until we are sure that the economic situation, and its effect on products demand, has ended.

We are particularly excited about the launch of *Primer Nivel Por Tu Salud,* our generic pharmaceuticals brand, since we believe that the market penetration of the generic pharmaceuticals industry in Mexico remains low and we plan to capitalize on the accelerated growth rates estimated for this industry in the coming years. Also, we believe that we have consolidated our business model and feel ready to enter the U.S. and Puerto Rican markets through our strategic alliance with Televisa.

We will continue to develop and launch innovative products under premium brands, supported by our continuous advertising strategy to drive growth in revenues, earnings and cash generation."

Consolidated Results of Operations for the Third Quarter of 2009

The following table shows our condensed and consolidated results of operations, in millions of pesos (except share and per-share data), the margin for each concept, as a percentage of Net Sales, as well as the variation in terms of percentage for the quarter and nine-month periods ended September 30, 2009 compared to the same period in 2008:

For the quarter and nine month periods ended September 30, 2009 and 2008
(In millions of current Mexican pesos)

	3rd Quarter			Jan - Sep		
	2009	**2008**	**%Var**	**2009**	**2008**	**%Var**
Net Sales	1,123.7	711.8	57.9	2,758.3	1,880.2	46.7
Gross Profit	783.7	538.1	45.6	1,985.8	1,421.6	39.7
Gross Margin	69.7%	75.6%	(5.9)	72.0%	75.6%	(3.6)
EBITDA[1]	296.8	206.7	43.6	646.4	478.9	35.0
EBITDA Margin[1]	26.4%	29.0%	(2.6)	23.4%	25.5%	(2.0)
Operating Income	273.8	201.6	35.8	602.8	466.5	29.2
Consolidated Net Income	186.1	150.7	23.5	383.9	320.1	19.9
Consolidated Net Income Margin	16.6%	21.2%	(4.6)	13.9%	17.0%	(3.1)
Weighted average number of shares outstanding	526,730,539	527,589,752	(0.2)	527,561,101	462,027,724	14.2
EPS (12 months)[2]	1.09	0.80	37.5	1.09	0.91	20.2

[1] EBITDA is calculated by adding pre-operative expenses, depreciation and amortization to the operating income. See EBITDA reconciliation below.

[2] Earnings per share are for the last 12 months and were calculated using the weighted average of shares outstanding for the period. The total number of shares outstanding as of September 30, 2009 totaled 526,632,713.

Net Sales rose 57.9% to Ps. 1,123.7 million for the third quarter of 2009, from Ps. 711.8 million for the third quarter of 2008. This increase resulted from the combination of the following: i) a 28.0% decrease (Ps. 175.3 million) from **Base Brands** in Mexico, to Ps. 451.0 million, including line extensions on these brands; ii) a 45.0% increase (Ps. 17.1 million) due to the full year effect of **Prior Year Launches** in Mexico, including recent line extensions on these brands launched during 2008 to reach Ps. 55.2 million; iii) Ps. 429.7 million in the third quarter of 2009 from **New Brands** in Mexico due to the launch of 181 new products under 13 New Brands during the year; and iv) a 295.9% increase (Ps. 140.4 million) in **International** operations to Ps. 187.8 million.

We classify Net Sales by brands in the following manner:

1) **Base Brands** were launched at least two years prior to the last fiscal year (2007, 2006, 2005, etc),
2) **Prior Year Launches** were brands launched during the prior fiscal year (2008),
3) **New Brands** were launched in the current fiscal year (2009), and
4) **International** refers to Net Sales from our international operations.

The following table shows Net Sales for the period detailed by brand:

(In millions of Pesos)

BRAND	NET SALES 3Q 09	% OF TOTAL NET SALES 3Q 09	NET SALES 3Q 08	VAR % 3Q 09 VS 08
PRIMER NIVEL	262.3	23.3%	0.0	100.0%
ASEPXIA	74.9	9.3%	63.0	18.9%
LINEA M	48.0	5.9%	96.3	-50.2%
GOICOECHEA	46.8	5.8%	43.8	6.8%
MA EVANS	44.4	5.5%	10.7	316.6%
QG5	39.2	4.9%	0.0	100.0%
CICATRICURE	33.2	4.1%	62.4	-46.7%
SUEROX	27.0	3.3%	0.0	100.0%
NIKZON	26.2	3.2%	39.6	-33.8%
SHOT B	25.5	3.2%	3.8	576.2%
UNESIA	25.1	3.1%	0.0	100.0%
SILKA MEDIC	23.4	2.9%	29.6	-20.8%
NEXT	23.3	2.9%	10.6	120.3%
OTHER BRANDS (<2%)	236.4	21.0%	304.6	-22.4%
TOTAL NATIONAL	935.9	83.3%	664.3	40.9%
INTERNATIONAL	187.8	16.7%	47.4	295.9%
TOTAL	1,123.7	100.0%	711.8	57.9%

Despite the strong variations in sales of the various brands, which reflect Genomma Lab's customers' inventory buildups and decreases from time to time, sell-out[6] growth of the national operations during the third quarter of 2009, compared to the same period of 2008 was 49.8%.

Gross Profit increased 45.6% to Ps. 783.7 million for the third quarter 2009 compared to Ps. 538.1 million during the third quarter of 2008. Gross Margin decreased 5.9 percentage points, as a percentage of Net Sales, to 69.7% in the third quarter of 2009, compared to 75.6% for the same period of 2008. This decrease was primarily attributable to a higher cost of goods sold as a percentage of Net Sales in our *Primer Nivel Por Tu Salud* products portfolio. Additionally, there was a change in the mix of products sales from the third quarter of 2008 to the third quarter of 2009 due to an increase in the percentage of the total sales from personal care products, which traditionally have a lower gross profit margin.

Selling, General and Administrative Expenses, as a percentage of Net Sales, decreased 1.9 percentage points to 45.4% for the third quarter of 2009 from 47.3% for the third quarter of 2008. This decrease was mainly due to a decline in accounts receivable reserves as a percentage of Net Sales mainly due to an improvement in our past due receivables. The decrease was partially offset by higher advertising expenses mainly as a result of the launch of the *Primer Nivel Por Tu Salud* Brand as well as an increase in our international commercial expenses, due to new product launches in our Colombian operations, which require special commercial support. Additionally, there was an increase in the Company's distribution expenses mainly as a result of the initial sale of *Primer Nivel Por Tu Salud* in order to build up inventory in the customers' stores.

EBITDA increased 43.6% to Ps. 296.8 million for the third quarter of 2009, compared to Ps. 206.7 million for the third quarter of 2008. The EBITDA margin decreased 2.6 percentage points as a percentage of Net Sales to 26.4% for the third quarter of 2009 from 29.0% for the third quarter of 2008. The EBITDA margin decrease was primarily due to a higher cost of goods sold as a percentage of Net Sales, associated with the launch of *Primer Nivel Por Tu Salud* which was partially offset by a decline in the Selling, General and Administrative Expenses as a percentage of Net Sales, for the aforementioned reasons.

[6] Sell-out represents Genomma Lab's customers sales at the point of sale. This statistics are measured internally and come from information obtained from a representative sample of our customers from which we can obtain this information on a regular basis.

EBITDA Reconciliation

For the third quarter period ended September 30, 2009 and 2008
(In thousands of current Mexican pesos)

	3Q	
	2009	2008
Consolidated net income (loss)	186.1	150.7
Discontinued operations	(1.8)	6.9
Income tax expense (benefit)	108.0	62.0
Comprehensive financing (income) cost	(19.8)	(26.5)
Other expense, Net	1.3	8.5
Income from operations	273.8	201.6
+ Pre-operative expenses	10.9	-
+ Depreciation and amortization	12.1	5.0
EBITDA	296.8	206.7
EBITDA margin	26.4%	29.0%

Operating Income increased 35.8% to Ps. 273.8 million for the third quarter of 2009 compared to Ps. 201.6 million for the third quarter of 2008. Operating margin decreased 4.0 percentage points, as a percentage of Net Sales, to 24.3%, compared to 28.3% for same period in 2008. This decline was primarily due to the aforementioned increases in the cost of goods sold as a percentage of Net Sales, in addition to an increase in depreciation and amortization due to the acquisition of fixed assets during the fourth quarter 2008 and during 2009; such as leasehold improvements and office equipment, as well as computer and transportation equipment.

Comprehensive Financing Income was Ps. 19.8 million for the third quarter of 2009, which represented a decrease of Ps. 6.7 million compared to the Ps. 26.5 million in the third quarter of 2008. The decrease was primarily a result of: i) lower interest income, to Ps. 6.3 million for the third quarter of 2009 from Ps. 21.9 million in the same period of 2008, primarily due to higher average cash balances in 2008 and a decrease in interest rate paid from bank accounts.; ii) an increase in the monetary position loss, to Ps. 1.4 million in the third quarter of 2009, compared to Ps. 0.4 million for the third quarter of 2008; iii) a foreign exchange gain of Ps. 15.5 million in the third quarter of 2009, from a Ps. 2.0 million gain during the same period of 2008, primarily due to the appreciation of U.S. dollar balances versus the Mexican peso for the period; iv) an increase in financial expenses of Ps. 2.1 million to Ps. 1.9 million during the third quarter of 2009 from Ps. 0.2 million during the same period of 2008; and v) a decrease in the effects of the exchange rate in foreign operations, to a gain of Ps. 1.3 million in the third quarter of 2009 from a gain of Ps. 2.8 million, due to the appreciation of the currencies in our operations during the corresponding periods. As of September 30, 2009, the Company maintained a U.S. dollar treasury position of US$ 22.7 million.

As of September 30, 2009, Genomma Lab had a total cash position of Ps. 1,019.2 million.

Consolidated Net Income increased 23.5% to Ps. 186.1 million for the third quarter of 2009 as compared to Ps. 150.7 million for the third quarter of 2008.

Balance Sheet

As of September 30, 2009, September 30, 2009 and December 31, 2008
(In millions of current Mexican pesos for the amounts of September 2009, September 2009 and December 2008)

	As of September 30, 2009	As of September 30, 2008	Var Sep 09 vs Sep 08	As of December 31, 2008	Var Sep 09 vs Dic 08
Balance Sheet Information:					
Cash and equivalents	1,019.2	1,066.0	(46.8)	1,291.0	(271.8)
Trade receivables	1,080.7	939.3	141.5	688.9	391.8
Inventories	647.0	307.7	339.2	407.7	239.3
Other current assets	298.7	134.0	164.7	206.6	92.1
Total Assets	3,755.9	2,695.8	1,060.1	2,839.9	916.0
Suppliers	564.6	281.5	283.1	377.2	187.4
Other current liabilities	341.2	312.3	28.9	134.1	207.1
Loans with financial institutions	-	0.1	(.1)	-	-
Total Liabilities	1,080.9	614.3	466.6	527.8	553.1
Stockholders Equity	2,675.0	2,081.5	593.5	2,312.1	362.9
Working Capital [1]	2,139.7	1,853.2	286.6	2,083.0	56.7
Working Capital less cash	1,120.5	787.2	333.3	792.0	328.6
Trade Recievables days	111	139	(28)	98	13
Inventories days	239	178	61	165	74
Suppliers days	208	163	45	58	151

[1] Working capital consists of current assets minus current liabilities.

Cash and Equivalents decreased 4.4% (Ps. 46.8 million) to Ps. 1,019.2 million on September 30 2009, compared to Ps. 1,066.0 million on September 30, 2008. This decrease was mainly due to cash consumption related to: i) the acquisition of 6 brands during the last 12 months for a total of Ps. 431.6 million, of which Ps. 281.6 million has been paid; ii) the transfer of shares to the stock repurchase program in the amount of Ps. 40.0 million; and iii) funding for the Employee Compensation Program in the amount of Ps. 95.0 million. This consumption was partially offset by the Company's cash generation of the last twelve months.

Trade Receivables increased 15.1% (Ps. 141.5 million) to Ps. 1,080.7 million on September 30, 2009 from Ps. 939.3 million on September 30, 2008. Days of Trade Receivables decreased 28 days, to 111 on September 30, 2009 from 139 on September 30, 2008. This decrease was mainly due to the standardized payment terms agreed with our customers.

Inventories increased 110.2% (Ps. 339.2 million) to Ps. 647.0 million on September 30, 2009 from Ps. 307.7 million on September 30, 2008. Days of Inventories increased 61 days, to 239 on September 30, 2009 from 178 on September 30, 2008. This increase was primarily as a result of: i) an increase in inventory as a result of the purchase of raw materials for new products which will be launched in the fourth quarter of 2009; ii) the creation of inventories for recent international operations; and iii) additional precautionary inventory purchases due to the high demand that our products have continued to demonstrate despite the current economic situation.

Suppliers increased 100.6% (Ps. 283.1 million) to Ps. 564.6 million on September 30, 2009, from Ps. 281.5 million on September 30, 2008. Days of Suppliers increased 45 days, to 208 on September 30, 2009 from 163 on September 30, 2008. This increase was due to an increase in payment terms negotiated with our suppliers to support our growth plan for the coming year end in addition to the effect caused by the launch of *Primer Nivel Por Tu Salud* which had special credit terms negotiated for the launch.

Other Current Assets increased 178.3% (Ps. 239.0 million) to Ps. 373.0 million on September 30, 2009 from Ps. 134.0 million on September 30, 2008. This change was attributable mainly to an increase in receivable taxes due to pending VAT tax refunds.

Other Current Liabilities increased 33.0% (Ps. 103.2 million) to Ps. 415.5 million on September 30, 2009 from Ps. 312.3 million on September 30, 2008. This change was attributable mainly to an increase in payable advertising during the period.

During the third quarter of 2009, cash flow from our operations and cash on hand was sufficient to meet our liquidity requirements.

Operations Summary

Net Sales for the Third Quarter

For the third quarter of 2009, Net Sales of our OTC pharmaceutical products decreased 10.6%[7] compared to the third quarter of 2008. During the third quarter of 2009, the Company launched four new OTC products.

Net sales of our personal care products increased 20.7%[8] for the third quarter of 2009 compared to the third quarter of 2008. During the third quarter of 2009 the Company launched nine new personal care products.

During the third quarter of 2009 the Company launched 167 new generic pharmaceutical products.

Net sales in our international operations increased 295.9% to Ps. 187.8 million for the third quarter of 2009 compared to Ps. 47.4 million for the same period in 2008. This increase was mainly driven by a strong growth in our Latin American operations and sales from the Colombian operations during the third quarter of 2009 which did not exist in the comparable period of 2008.

New Products Launches and Line Extensions

During 2009, we have launched 14 line extensions of **Base Brands** and **Prior Year Launches;** and 181 new products under 13 **New Brands**; among these were:

Unesia is a new brand which consists in a topical OTC treatment for nail fungus. *Unesia* is an innovative product in the category it participates in most of the other available treatments are oral and can be expensive, uncomfortable and can take a long time to work.

Coledia is a new brand which consists in a multivitamin product that aids in the reduction of cholesterol levels.. *Coledia* is an ideal product for people with hereditary high cholesterol levels as well as an excellent precautionary measure.

Shot B for Diabetics is a line extension of our Shot B (B vitamin OTC brand). The launch is in response to recent market studies, which show that vitamin B helps control and reduce discomforts produced by diabetes.

[7] Includes only OTC pharmaceutical products in Mexico.
[8] Includes only personal care products in Mexico.

Other Events

- During the third quarter the Company launched *Primer Nivel Por Tu Salud* brand to commercialize generic pharmaceuticals with a marketing campaign which highlights the advantages of buying generics versus expired patent pharmaceuticals. This brand will be commercialized through the subsidiary of Medicinas y Medicamentos Nacionales, S.A. de C.V., which was acquired by the Company during the first quarter of 2009.

- Genomma Lab has closed a strategic alliance agreement to sell and distribute personal care products and OTC pharmaceuticals in the U.S. and Puerto Rico. The strategic alliance will operate through Televisa Consumer Products USA ("TCP") a company owned 51% by Televisa and 49% by Genomma Lab. The sale and distribution of Genomma Lab's products will be an integral part of the activities of TCP. As part of this alliance, TCP entered into, among others, a product supply agreement with Genomma Lab. Televisa will make available its different media platforms in the U.S. and Puerto Rico to TCP, which will provide Genomma Lab brands with significant advertising in the targeted markets in line with Genomma Lab´s business model. This will enable Genomma Lab to expand the extensive success of its brands beyond Mexico and Latin America by accessing a Hispanic market of approximately 50 million consumers with a purchasing power of over US$ 870 billion annually while leveraging Televisa's reach and name recognition in the Hispanic market. Genomma Lab expects to begin operations during the first quarter of 2010.

- During the third quarter the Company continued its preparation to launch operations in Brazil. Genomma Lab expects to begin operations during the first quarter of 2010.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Mexico. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. Through a combination of a successful new products development process, consumer-oriented marketing, a broad retail distribution network and a low-cost, highly flexible operating model.

Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg: labb.mx).

Note on Forward-Looking Statements

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Income Statement

Genomma Lab Internacional S.A.B. de C.V.

Consolidated statements of operations

For the three months and nine months periods ended September 30, 2009 and 2008.
(In thousands of current Mexican pesos)

		3Q				YTD		
		2009	**2008**	**% Var**		**2009**	**2008**	**% Var**
Net sales		1,123,719	711,772	57.9%		2,758,296	1,880,230	46.7%
Costs and expenses:								
Cost of sales		340,050	173,643	95.8%		772,546	458,591	68.5%
Selling, general and administrative expenses		509,910	336,483	51.5%		1,382,952	955,142	44.8%
Total costs and expenses		849,960	510,126	66.6%		2,155,497	1,413,733	52.5%
Income from operations		273,758	201,646	35.8%		602,798	466,498	29.2%
Other (expense)- Net		(1,278)	(8,480)	-84.9%		(1,341)	(7,074)	-81.0%
Comprehensive financing income (cost)								
Interest (expense)		(1,963)	165	-1287.7%		(7,046)	(15,119)	-53.4%
Interest income		6,349	21,882	-71.0%		33,728	24,762	36.2%
Exchange gain (loss)		15,535	2,022	668.4%		(23,070)	3,199	-821.2%
Monetary position (loss)		(1,423)	(419)	239.5%		(4,063)	(1,807)	124.9%
Effects of exchange rate changes on foreign o		1,298	2,839	-54.3%		1,365	276	394.6%
		19,795	26,489	-25.3%		914	11,312	-91.9%
Income before income taxes		292,275	219,655	33.1%		602,371	470,736	28.0%
Income tax expense (benefit)		107,969	61,982	74.2%		219,163	136,771	60.2%
Discontinued operations (loss)		1,799	(6,939)	-125.9%		738	(13,852)	-105.3%
Consolidated net income (loss)	$	186,105	150,734	23.5%	$	383,946	320,112	19.9%
Consolidated net income (loss)	$	186,105	150,734	23.5%	$	383,946	320,112	19.9%
Net loss (income) of minority stockholders	$	(1,626)	614	-364.8%	$	(2,518)	1,428	-276.3%
Net income of majority stockholders	$	184,479	151,348	21.9%	$	381,428	321,541	18.6%

Balance Sheet

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

Consolidated balance sheets
For the period September 2009, September 2008 and December 2008
(In thousands of current mexican Pesos)

	Sep-09	Sep-08	V$	V%	Dec-08	V$	V%
Assets							
Current assets:							
Cash and equivalents	1,019,198	1,065,983	(46,785)	-4.4%	1,291,048	(271,850)	-26.7%
Share buy back fund	16,131	6,381	9,750	0.0%	24,084	(7,953)	-49.3%
Employee Share buy back fund	15,499		15,499	0.0%		15,499	100.0%
Accounts receivable-Net	1,283,081	996,369	286,712	28.8%	755,108	527,973	41.1%
Inventory - Net	646,960	307,722	339,239	110.2%	407,710	239,250	37.0%
Prepaid expenses and other current assets	49,335	46,264	3,071	6.6%	104,477	(55,142)	-111.8%
Due from related parties	15,371	24,274	(8,903)	-36.7%	11,887	3,484	22.7%
Discontinued operations	23,191	26,253	(3,062)	-11.7%	22,917	274	1.2%
Total current assets	**3,068,766**	**2,473,245**	**595,521**	**24.1%**	**2,617,231**	**451,535**	**14.7%**
Equipment- net	**163,245**	**90,417**	**72,828**	**80.5%**	**107,715**	**55,530**	**34.0%**
Trademarks	435,879	78,691	357,187	453.9%	80,626	355,253	81.5%
Investments in subsidiaries	0	13	(13)	0.0%	-	0	100.0%
Investments available for sale							
Deferred income tax	29,486	39,905	(10,419)	-26.1%	1,108	28,378	96.2%
Other assets- Net	58,138	11,659	46,479	398.7%	32,820	25,318	43.5%
Discontinued operations	432	1,893	(1,461)	-77.2%	424	8	1.8%
	523,935	**132,161**	**391,774**	296.4%	**114,979**	**408,956**	78.1%
Total Assets	**3,755,947**	**2,695,824**	**1,060,123**	**39.3%**	**2,839,926**	**916,021**	**24.4%**
Current Liabilities:							
Loans with financial institutions	-	60	(60)	-100.0%	-	-	NA
Trade accounts payable	564,616	281,506	283,109	100.6%	377,180	187,436	33.2%
Due to related parties	35	119	(85)	0.0%	119	(85)	-243.8%
Accrued expenses and taxes other than income taxes	205,362	177,243	28,119	15.9%	99,350	106,012	51.6%
Deferred Income	-	20,051	(20,051)	0.0%	-	-	NA
Income tax payable	135,844	114,914	20,931	18.2%	34,665	101,179	74.5%
Statutory employee profit sharing	5,164	780	4,383	561.6%	1,838	3,326	64.4%
Discontinued operations	4,335	10,755	(6,420)	-59.7%	9,871	(5,536)	-127.7%
Deferred income tax	-	-	-	0.0%		-	NA
Employee retirement obligations	7,401	8,895	(1,494)	-16.8%	4,765	2,635	35.6%
Trade accounts payable LP	158,156	-	158,156	100.0%	-	158,156	100.0%
			-			-	
Total Liabilities	**1,080,912**	**614,323**	**466,589**	**76.0%**	**527,788**	**553,124**	**51.2%**
Capital stock	274,924	1,795,468	(1,520,545)	-84.7%	274,924	0	0.0%
Additional paid in capital	1,553,938	-	1,553,938	0.0%	1,553,938	-	0.0%
Retained earnings	519,636	(33,878)	553,514	-1633.8%	(37,296)	556,933	107.2%
Net income	381,428	321,541	59,887	18.6%	515,776	(134,347)	-35.2%
Cumulative translation effects of foreign subsidiaries	2,065	(1,631)	3,695	-226.6%	4,796	(2,732)	-132.3%
Share buyback fund	(65,037)	-	(65,037)	0.0%	-	(65,037)	100.0%
Interés minoritario	8,081						
Total stockholders equity	**2,675,035**	**2,081,501**	**585,453**	**28.1%**	**2,312,137**	**362,897**	**13.6%**

Cash Flow Statement

Genomma Lab Internacional S.A.B. de C.V. and subsidiaries

Consolidated cash flow statement

	2009 3Q	2009 YTD
Operating activities:		
Income for continued operations	$292,275	$602,371
Items that did not require resources:		
Depreciation and amortization	12,131	27,158
Not realized foreign exchange gains or losses	(171)	118
Gain on fixed assets sale	8	(11)
Income tax	63,762	110,128
Employee termination obligations, net	879	2,636
Employee profit sharing	1,586	3,326
Other financing activites	579	4,805
Cash flow from operations	371,050	750,532
(Increase) Decrease in accounts receivable	(626,498)	(708,055)
(Increase) Decrease in inventories	(130,005)	(238,728)
Increase (Decrease) in accounts payable	270,921	260,963
Increase (Decrease) in payable tax	(68,658)	(45,228)
Other, Net	30,744	55,142
Shared based payments	10,311	29,277
Discontinued operations	(1,914)	(5,071)
Changes in Working Capital	(515,098)	(651,700)
Net cash flow generated (used) in operating activities	(144,048)	98,832
Loss in discontinued operations	-	-
Net Cash flow generated (used) in operating activities after discontined operations	(144,048)	98,832
Investing activities:		
Divestments (investments)	(34,640)	(75,209)
Asset sales (other capital expenditures)	(19,533)	(232,020)
Discontinued operations	(27)	(7)
Net cash flow from investing activities	(54,200)	(307,236)
Net cash genereted to aply in financing activities	(198,248)	(208,404)
Financing activities:		
Stock repurchases	(1,175)	(52,938)
Payable interest from prior periods	(579)	(4,805)
Gain on stock repurchases	0	(221)
Minority interest	4,538	4,787
Net cash flow provided from financing activities	2,784	(53,177)
Net increase in cash and equivalentes before foreign exchange adjustments coming from International operations and inflationary effects.	(195,464)	(261,581)
Foreign exchange and inflationary effects from International operations	(1,114)	(2,723)
Net increase (decrease) in cash	(196,578)	(264,304)
Cash and equivalents beginning of period	1,247,406	1,315,132
Cash and equivalente end period balance.	**1,050,828**	**1,050,828**
less- purchasing shares found	16,131	16,131
less- Employees shares found	15,499	15,499
Cash and equivalente end period balance for operation	1,019,198	1,019,198